
India's IT layoffs spark fears that AI is hurting jobs in a sector critical to its economy
The country's largest private sector employer, Tata Consultancy Services, which employs over half a million IT workers, announced last month that it would cut more than 12,000 jobs from mostly the middle and senior management levels, equating to 2% of its global workforce — in what will be its biggest layoff so far.
The company's CEO and managing director K Krithivasan attributed the move to "limited deployment opportunities and skill-mismatch" rather than AI. But that did not quell growing unease within the country, as many viewed the layoffs as a sign of broader and disruptive changes underway in the IT sector, amplified by the growing influence of AI.
TCS and its peers have long relied on India's vast pool of low-cost, skilled labor to produce software services, a model now coming under pressure as AI is set to automate repetitive tasks and as global clients demand higher levels of innovation.
The IT sector has long been highly sought after among India's large pool of engineering graduates, meaning any slowdown will have ripple effects across the economy. India produces over 1.5 million engineering graduates annually, according to local media reports.
The sector contributed roughly 7.5% to India's gross domestic product in fiscal year 2023.
"AI adoption is a major challenge for India. Entry level routine jobs are being displaced, and mid-level jobs are transforming," said Sonal Varma, chief economist of India and Asia ex-Japan at Nomura.
"This creates the challenge for job creation for India, since the country needs to create about 8 [million] jobs annually," she added.
Recent earnings also painted a sobering picture of the sector's performance, with IT majors such as TCS, Infosys and Wipro reporting muted year-on-year growth.
Although that was largely attributed to uncertainty around U.S. tariffs, which weighed on American clients' budgeting confidence, the recent signs of slowdown in India's IT sector may be merely a "cyclical change," as services exports to the U.S. have eased, said Dhiraj Nim, economist and foreign exchange strategist at ANZ Research.
AI, however, will be "a trend to reckon with in the years to come," Nim added.
New Delhi has been striving to incentivize growth in labor-intensive manufacturing sectors such as electronics, textiles, footwear and toys as part of its supply chain relocation strategy.
The layoffs also add to an already strained labor market as the country's unemployment rate continued to rise. India's urban unemployment rate rose to 7.1% in June from 6.9% in May and 6.5% in April. The youth unemployment rate in urban areas, among those aged 15 to 29 years, also spiked to nearly 19% from 17.9% in May, and 17.2% in April, according to the statistics ministry.
The labor market problem could persist for a few years, said Anubhuti Sahay, head of South Asia economic research at Standard Chartered, urging New Delhi to ramp up efforts in creating more salaried jobs.
She pointed out that the bulk of job creation has so far come from self-employed sectors where wages tend to remain lower than in salaried ones.
Economists have urged New Delhi to accelerate its efforts in upskilling its labor force and bridge the skill gap to lower the risk of job displacement. One in five young adults in India have participated in an AI-skilling program, according to a report supported by Google.org and Asian Development Bank.
AI will replace some jobs but also transform the nature of existing jobs through "constant skilling," Nomura's Varma said.
The government has rolled out an internship program aimed up skilling younger adults with actual working experience.
Nim acknowledged that AI could be a threat to jobs, but suggested that whether it will lead to increasing job displacement will depend on skilling and labor movement up the skill chain.
New Delhi also must pivot to higher value-added services and innovation rather than focusing on low-end routine work, economists said.
"If the economy is unable to adapt, this could lead to job losses, lower services exports, moderate urban consumption," said Varma, with ripple effects across real estate, retail and ancillary services.
"It could risk India getting stuck in the middle-income trap," Varma added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
Press Release Nicox's Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in Japan Triggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial of NCX 470 (also known as K-911) in Japan for the treatment of ocular hypertension, triggering a €2 million milestone payment to Nicox. Only one Phase 3 confirmatory clinical trial in Japanese patients, which will start shortly, plus this safety trial, is required for submission for marketing approval of NCX 470 in Japan. Kowa is responsible for financing and managing the trials under the February 2024 license agreement with Nicox.'Thanks to our continuing collaborative efforts after Kowa received approval to initiate this trial, we are very pleased to announce that the first patient has been enrolled. The Phase 3 trials in Japan are being managed and financed by Kowa, and only one confirmatory Phase 3 trial is expected to be needed to make a submission for marketing approval of NCX 470 in Japan.' said Doug Hubatsch, EVP Scientific Officer of Nicox. The trial announced today is a safety trial and is detailed here: JRCT Safety Trial NCX 470. The 500 patient confirmatory trial is expected to start shortly and is detailed here: JRCT Confirmatory Trial NCX NCX 470NCX 470, Nicox's lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development programs in the U.S., China and Japan for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the Phase 3 clinical trials, have been extensively published and are available on our website. All patients have completed the second Phase 3 clinical trial, Denali, and topline results are expected mid-August to mid-September 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China. A separate Phase 3 clinical program is underway to support Japanese approval. NCX 470 is exclusively licensed to Ocumension Therapeutics in China, Korea and Southeast Asia and to Kowa in the rest of the world. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NCX470KowaFPFVAugust2025_PR_FINAL


Business Upturn
5 minutes ago
- Business Upturn
TCS secures five-year contract renewal and expansion with Weatherford International
By Aman Shukla Published on August 5, 2025, 11:04 IST Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a global IT services and consulting leader, has announced a major five-year contract renewal and expansion with Weatherford International (NASDAQ: WFRD), a leading oilfield services company headquartered in North America. This strategic partnership builds on a trusted relationship of over seven years, during which TCS has delivered significant value through business process optimization. Under the renewed agreement, TCS will drive enterprise-wide digital transformation initiatives for Weatherford, with a strong focus on leveraging automation, artificial intelligence (AI), and digital optimization to improve operational efficiencies. The expanded scope includes transformation advisory services to align operations with Weatherford's broader digital excellence goals. Key areas of collaboration include enhancing critical business functions across finance, supply chain, and human resources. TCS will introduce AI-powered solutions to streamline Weatherford's finance and accounting workflows, reduce operational costs, and improve scalability. Additionally, the initiative aims to simplify processes, boost innovation, and implement outcome-based strategies for sustainable growth and long-term agility. Over the past seven years, TCS has played a pivotal role in reducing Weatherford's total cost of ownership by nearly 50% across key operations. With this new phase, TCS will integrate its advanced digital capabilities to further empower Weatherford to adapt to evolving market conditions and maximize resource efficiency. TCS brings deep industry experience, working with four of the world's top five oilfield service companies. Its service offerings span Consulting and Systems Integration, ERP, Cloud, Cybersecurity, Application Maintenance, Testing, and Digital Technologies—making it a trusted transformation partner in the energy sector. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
32 minutes ago
- Yahoo
Asian Market Value Picks: 3 Companies That May Be Trading Below Intrinsic Estimates
Amidst global economic uncertainties and fluctuating trade policies, Asian markets have shown resilience, with varying impacts on indices across the region. This environment presents opportunities for discerning investors to explore stocks that may be trading below their intrinsic value, particularly those with strong fundamentals and potential for growth despite external pressures. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xi'an NovaStar Tech (SZSE:301589) CN¥155.51 CN¥309.46 49.7% SpiderPlus (TSE:4192) ¥506.00 ¥997.79 49.3% Ningbo Sanxing Medical ElectricLtd (SHSE:601567) CN¥22.88 CN¥45.72 50% Nanya Technology (TWSE:2408) NT$43.75 NT$87.13 49.8% Nan Ya Printed Circuit Board (TWSE:8046) NT$176.50 NT$350.51 49.6% Insource (TSE:6200) ¥926.00 ¥1843.53 49.8% H.U. Group Holdings (TSE:4544) ¥3254.00 ¥6446.96 49.5% Elan (TSE:6099) ¥850.00 ¥1696.06 49.9% cottaLTD (TSE:3359) ¥441.00 ¥871.25 49.4% Astroscale Holdings (TSE:186A) ¥676.00 ¥1333.68 49.3% Click here to see the full list of 274 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Beijing HyperStrong Technology Overview: Beijing HyperStrong Technology Co., Ltd. designs, develops, integrates, and operates energy storage power stations across China, Europe, North America, and Australia with a market cap of CN¥16.64 billion. Operations: The company's revenue segments include the design, development, integration, and operation of energy storage power stations across its key markets in China, Europe, North America, and Australia. Estimated Discount To Fair Value: 37.2% Beijing HyperStrong Technology is trading at CN¥92.37, significantly below its estimated fair value of CN¥147.06, suggesting it may be undervalued based on cash flows. Its revenue and earnings are forecast to grow over 30% annually, outpacing the Chinese market's growth rates. However, its dividend yield of 1.19% is not well covered by free cash flows. Recent innovations like the HyperBlock M enhance its competitive edge in energy storage solutions through modularity and efficiency improvements. Upon reviewing our latest growth report, Beijing HyperStrong Technology's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of Beijing HyperStrong Technology stock in this financial health report. Shenzhen KSTAR Science and Technology Overview: Shenzhen KSTAR Science and Technology Co., Ltd. operates in the technology sector, focusing on power electronics and renewable energy solutions, with a market cap of CN¥13.86 billion. Operations: Unfortunately, the provided text does not contain specific revenue segment information for Shenzhen KSTAR Science and Technology Co., Ltd. Estimated Discount To Fair Value: 48.5% Shenzhen KSTAR Science and Technology is trading at CN¥23.8, well below its estimated fair value of CN¥46.24, indicating potential undervaluation based on cash flows. The company's revenue is projected to grow 22.3% annually, surpassing the Chinese market's average growth rate. Despite a forecasted earnings growth of 32.4%, profit margins have declined from last year, and the dividend track record remains unstable with recent reductions in payouts for 2024 dividends. The growth report we've compiled suggests that Shenzhen KSTAR Science and Technology's future prospects could be on the up. Click here to discover the nuances of Shenzhen KSTAR Science and Technology with our detailed financial health report. Qingdao Baheal Medical Overview: Qingdao Baheal Medical INC. is involved in the research, development, production, wholesale, and retail of pharmaceutical products across China, the United States, Hong Kong, and the United Kingdom with a market cap of CN¥11.77 billion. Operations: Qingdao Baheal Medical INC. generates revenue through its activities in the research, development, production, wholesale, and retail sectors of pharmaceutical products across several international markets including China, the United States, Hong Kong, and the United Kingdom. Estimated Discount To Fair Value: 18.5% Qingdao Baheal Medical, trading at CN¥22.39, is priced below its fair value estimate of CN¥27.46, reflecting potential undervaluation based on cash flows. Despite a volatile share price recently, earnings are projected to grow significantly at 20.05% annually over the next three years, although this lags behind the broader Chinese market's growth rate. The company affirmed a dividend payout for 2024, which may appeal to income-focused investors amid stable revenue growth projections of 13% per year. In light of our recent growth report, it seems possible that Qingdao Baheal Medical's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of Qingdao Baheal Medical. Turning Ideas Into Actions Unlock more gems! Our Undervalued Asian Stocks Based On Cash Flows screener has unearthed 271 more companies for you to here to unveil our expertly curated list of 274 Undervalued Asian Stocks Based On Cash Flows. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688411 SZSE:002518 and SZSE:301015. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data